Drugs / BN102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05365100 | Jul 2022 → Jul 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | BioNova Pharmaceuticals (Shanghai) LTD. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BN102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05365100 ↗ |
| Route | Oral | “oral tablets: BN102, BID” NCT05365100 ↗ |